Today, at the 2026 Boston Animal Health, Nutrition and Technology Innovation (AHNTI) Conference, VETARYS (www.vetarys.com) announced a research collaboration and option for an exclusive license for a canine combination immunotherapy being developed as a fusion protein by Antigenesis Biologics (www.antigenesis-bio.com), targeting solid tumors in dogs.
Antigenesis builds on the latest advances in proven human immunotherapies to develop first-in-class antibody therapeutics for companion animals, starting with canine oncology.
“Today’s standard-of-care treatments for cancer in dogs remain largely limited to radiation and chemotherapy with variable efficacy and significant side effects,” said Peter Hanson, Chief Scientific Officer at VETARYS. “The fusion protein being developed by Antigenesis combines two immunotherapies that together have demonstrated compelling improvements in survival and tumor shrinkage in the severe mouse melanoma model. Our target is to develop a subcutaneous therapy that can be administered by primary care veterinarians as a complement to veterinary oncology specialists, whose numbers are too few to reach every dog that needs cancer care.”
About Antigenesis Biologics
Antigenesis Biologics, Ltd. is a biotech company dedicated to addressing critical unmet needs in veterinary medicine. Leveraging our expertise in human therapeutics, we bring state-of-the-art advances to the significantly underserved veterinary market. Antigenesis develops targeted, safe, and effective treatments for oncology and other serious conditions, with a current pipeline focused on canine oncology and endocrine diseases. Our mission is to accelerate innovation and improve the health and well-being of our animal family members.
VETARYS, Inc. (formerly known as VetrixBio) is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicine, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. VETARYS centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, VETARYS is committed to bringing the next generation of veterinary medicines to market.
Vetarys, Inc.
9 Centennial Drive
2nd Floor, Suite 6832
Peabody, MA 01960
info@vetarys.com
This press release contains forward-looking statements, including statements regarding the development, potential efficacy, and future progress of Vetarys’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Vetarys undertakes no obligation to update these statements except as required by law.
